Combination Therapy for Metastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Combination Therapy for Metastatic Renal Cell Carcinoma

Published:2020-04-03 Issue:7 Volume:43 Page:477-483
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Alam Muhammad U.,Jazayeri Seyed B.,Gautam Shiva,Norez Daniel,Kumar Jatinder,Tanneru Karthik,Nguyen Sabine,Costa Joseph,Bandyk Mark,Ganapathi Hariharan P.,Koochekpour Shahriar,Balaji K.C.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference23 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

2. Renal cancer;Capitanio;Lancet,2016

3. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Motzer;N Engl J Med,2019

4. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

5. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial;Rini;Lancet,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis;Health Technology Assessment;2024-08

2. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma;European Urology;2021-12

3. Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma;Clinical Genitourinary Cancer;2021-10

4. Symptomatic Pituitary Metastasis as Initial Manifestation of Renal Cell Carcinoma: Case Report and Review of Literature;Case Reports in Endocrinology;2020-08-18